Mechanism of Action of Focal Extracorporeal Shock Waves as a Treatment of Upper Limb Stroke Spasticity: a Pilot Study
NCT ID: NCT06311526
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
OBSERVATIONAL
2023-05-30
2025-03-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
There are different spasticity treatments, such as botulinum neurotoxin, in the first place. Among the emerging therapies is focal extracorporeal shock wave therapy, consisting of a sequence of sonic (mechanical) impulses with high peak pressure.
Systematic reviews highlighted that shock waves effectively improve lower and upper limb spasticity. Moreover, the shock waves therapeutic effect can last up to 12 weeks from the last treatment session.
When used to treat stroke spasticity, the shock waves' mechanism of action is poorly detailed.
On the one side, shock waves could change the physical properties of the muscular tissue (e.g. viscosity, rigidity).
On the other, the shock waves produce a robust mechanical stimulation that massively activates muscle and skin mechanoreceptors (e.g. muscle spindles). This activation would modulate, in turn, the spinal (and supra-spinal) circuits involved in spasticity.
To our knowledge, no study investigated the shock waves mechanism of action in stroke upper limb spasticity.
Research question: do shock waves exert their therapeutic effect on spasticity by changing the muscle's physical properties or by indirectly modulating the excitability of spinal circuits?
Specific aims: To investigate the mechanism of action of shock wave therapy as a treatment of upper limb spasticity after a stroke.
Two major hypotheses will be contrasted: shock waves reduce hypertonia 1) by changing the muscle's physical features or 2) by changing the motoneurons excitability and the excitability of the stretch reflex spinal circuits.
Shock wave therapy is expected to improve spasticity, thus improving the following clinical tests: the Modified Ashworth Scale (an ordinal score of spasticity) and the Functional Assessment for Upper Limb (FAST-UL, an ordinal score of upper limb dexterity).
This clinical improvement is expected to be associated with changes in spastic muscle echotexture assessed with ultrasounds, such as an improvement in the Heckmatt scale (an ordinal score of muscle echotexture in spasticity).
Clinical improvement is also expected to be associated with an improvement in the following neurophysiological parameters: a reduction of the H/Mmax ratio (an index of hyperexcitability of the monosynaptic stretch reflex circuit), a decrease in amplitude of the F waves (a neurophysiological signal reflecting the excitability of single/restricted motoneurones) and an increase of the homosynaptic depression (also known as post-activation depression, reflecting the excitability of the transmission between the Ia fibres and motoneurones).
Understanding the shock wave mechanism of action will lead to a better clinical application of this spasticity treatment.
If the shock waves exert their therapeutic effect by changing the muscle's physical properties, they could be more appropriate for patients with muscle fibrosis on ultrasounds.
On the contrary, if the shock waves work on spasticity by indirectly acting on the nervous system's excitability, then a neurophysiology study could be used to preliminary identify the muscle groups with the most significant neurophysiological alterations, which could be the muscles benefitting the most from this treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness of Shock Wave Therapy for Upper Limb Spasticity
NCT04316026
Focal Muscular Vibration to Treat Upper Limb Spasticity in Stroke
NCT04087928
Combined Antagonistic Muscle Magnetic Stimulation and Selective Periferal Neurotomy to Improve Results on Spasticity
NCT02226432
Comparing the Effect of Focused and Radial Extracorporeal Shock Waves on Post-stroke Hypertonia
NCT03129529
Benefits of Extracorporeal Shockwave Therapy to Reduce Spasticity in Stroke/CP
NCT06548321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stroke patients suffering a spastic upper limb paresis
Extracorporeal Shockwave Therapy
Extracorporeal Shockwave Therapy administered to the belly of spastic muscles of the upper limb.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Extracorporeal Shockwave Therapy
Extracorporeal Shockwave Therapy administered to the belly of spastic muscles of the upper limb.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* first hemispheric stroke at least six months ago
* spasticity of wrist and elbow flexors muscles with grade 1 to 3 of the Modified Ashworth Scal
* no botulinum toxin injection in the previous six months
* ability to give informed consent
Exclusion Criteria
* presence of a pacemaker, an implantable cardioverter defibrillator or other medical devices
* active cancer
* skin lesions at the site of shock wave administration
* an major neurological disease in addition to the hemiparesis (e.g. spastic hemiparesis in a patient who had Parkinson's disease before their stroke).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituto Auxologico Italiano
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Istituto Auxologico Italiano
Milan, MI, Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013 Jan 15;80(3 Suppl 2):S13-9. doi: 10.1212/WNL.0b013e3182762448.
Manganotti P, Amelio E. Long-term effect of shock wave therapy on upper limb hypertonia in patients affected by stroke. Stroke. 2005 Sep;36(9):1967-71. doi: 10.1161/01.STR.0000177880.06663.5c. Epub 2005 Aug 18.
Opara J, Taradaj J, Walewicz K, Rosinczuk J, Dymarek R. The Current State of Knowledge on the Clinical and Methodological Aspects of Extracorporeal Shock Waves Therapy in the Management of Post-Stroke Spasticity-Overview of 20 Years of Experiences. J Clin Med. 2021 Jan 12;10(2):261. doi: 10.3390/jcm10020261.
Pierrot-Deseilligny, E. & Burke, D. Contribution of Spinal Pathways to the Pathophysiology of Movement Disorders. The Circuitry of the Human Spinal Cord 565-579 (2012) doi:10.1017/CBO9781139026727.015.
Kohn AF, Floeter MK, Hallett M. Presynaptic inhibition compared with homosynaptic depression as an explanation for soleus H-reflex depression in humans. Exp Brain Res. 1997 Sep;116(2):375-80. doi: 10.1007/pl00005765.
Lundbye-Jensen J, Nielsen JB. Immobilization induces changes in presynaptic control of group Ia afferents in healthy humans. J Physiol. 2008 Sep 1;586(17):4121-35. doi: 10.1113/jphysiol.2008.156547. Epub 2008 Jul 3.
Lamy JC, Wargon I, Mazevet D, Ghanim Z, Pradat-Diehl P, Katz R. Impaired efficacy of spinal presynaptic mechanisms in spastic stroke patients. Brain. 2009 Mar;132(Pt 3):734-48. doi: 10.1093/brain/awn310. Epub 2008 Nov 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24C303
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.